share_log

Merck & Co | 8-K: Merck Announces Second-Quarter 2024 Financial Results

Merck & Co | 8-K: Merck Announces Second-Quarter 2024 Financial Results

默沙東 | 8-K：默沙東公佈 2024 年第二季度財務業績
美股SEC公告 ·  07/30 18:46
牛牛AI助理已提取核心訊息
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the second quarter of 2024 on July 30, 2024. The company saw a 7% increase in total worldwide sales compared to the second quarter of 2023, reaching $16.1 billion. This growth was attributed to an 11% increase excluding the impact of foreign exchange. KEYTRUDA, Merck's cancer drug, experienced a 16% sales growth to $7.3 billion, with an even higher growth rate of 21% excluding foreign exchange influences. The company's GAAP earnings per share (EPS) was $2.14, while non-GAAP EPS was $2.28. Merck also highlighted the successful initial launch of WINREVAIR in the U.S. and positive opinions from the EU CHMP for adults with PAH. Additionally, the company completed acquisitions of EyeBio and Elanco's Aqua Business...Show More
Merck & Co., Inc., a leading pharmaceutical company, reported its financial results for the second quarter of 2024 on July 30, 2024. The company saw a 7% increase in total worldwide sales compared to the second quarter of 2023, reaching $16.1 billion. This growth was attributed to an 11% increase excluding the impact of foreign exchange. KEYTRUDA, Merck's cancer drug, experienced a 16% sales growth to $7.3 billion, with an even higher growth rate of 21% excluding foreign exchange influences. The company's GAAP earnings per share (EPS) was $2.14, while non-GAAP EPS was $2.28. Merck also highlighted the successful initial launch of WINREVAIR in the U.S. and positive opinions from the EU CHMP for adults with PAH. Additionally, the company completed acquisitions of EyeBio and Elanco's Aqua Business in July 2024. Merck raised its full-year 2024 financial outlook, expecting worldwide sales to be between $63.4 billion and $64.4 billion, and non-GAAP EPS to be between $7.94 and $8.04, reflecting a negative impact from a one-time charge for the acquisition of EyeBio. The company's chairman and CEO, Robert M. Davis, expressed pride in the team's efforts to advance the pipeline and deliver innovative solutions to medical needs.
領先藥品公司默沙東於2024年7月30日公佈了其2024年第二季度的財務報告。與2023年第二季度相比，全球銷售額增長了7%，達到了161億美元。這種增長歸因於除匯率期貨影響外的11%的增長。默沙東的癌症藥品KEYTRUDA的銷售額增長了16%，達到了73億美元，除外匯期貨影響的增長率更高達21%。該公司的按照美國通用會計準則計算的每股收益是2.14美元，而非通用會計準則的每股收益是2.28美元。此外，默沙東還強調了WINREVAIR在美國的成功首次推出以及歐盟CHMP對PAH成人的積極意見。此外，該公司於2024年7月完成了EyeBio和Elanco Aqua業務的收購。默沙東提高了其2024年全年財務前景，預計全球銷售額爲634億至644億美元，非通用會計準則的每股收益爲7.94至8.04美元，反映了一次收購EyeBio的一次性費用的負面影響。該公司的董事長兼CEO羅伯特·M·戴維斯對團隊推進管道和爲醫療需求提供創新解決方案感到自豪。
領先藥品公司默沙東於2024年7月30日公佈了其2024年第二季度的財務報告。與2023年第二季度相比，全球銷售額增長了7%，達到了161億美元。這種增長歸因於除匯率期貨影響外的11%的增長。默沙東的癌症藥品KEYTRUDA的銷售額增長了16%，達到了73億美元，除外匯期貨影響的增長率更高達21%。該公司的按照美國通用會計準則計算的每股收益是2.14美元，而非通用會計準則的每股收益是2.28美元。此外，默沙東還強調了WINREVAIR在美國的成功首次推出以及歐盟CHMP對PAH成人的積極意見。此外，該公司於2024年7月完成了EyeBio和Elanco Aqua業務的收購。默沙東提高了其2024年全年財務前景，預計全球銷售額爲634億至644億美元，非通用會計準則的每股收益爲7.94至8.04美元，反映了一次收購EyeBio的一次性費用的負面影響。該公司的董事長兼CEO羅伯特·M·戴維斯對團隊推進管道和爲醫療需求提供創新解決方案感到自豪。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。